Your browser doesn't support javascript.
Clinical Application of Inhaled Ciclesonide and Enoxaparin for COVID-19 Pneumonia
International Journal of Gerontology ; 16(2):144-146, 2022.
Article in English | English Web of Science | ID: covidwho-1884654
ABSTRACT
The novel coronavirus disease 2019 (COVID-19) pandemic is a threat to global public health. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and characterized by high transmission, high mortality, lack of effective treatment, and prolonged hospitalization. Currently, there is no clear management strategy for COVID-19 infection. Some clinical evidence suggests that the use of inhaled ciclesonide and enoxaparin subcutaneous injection maybe helpful for disease treatment. In this article, we report the successful treatment of a 65-year-old male with COVID-19 pneumonia with Inhaled corticosteroid and enoxaparin subcutaneously, which also shortened the course of the disease without significant complications. Copyright (C) 2022, Taiwan Society of Geriatric Emergency & Critical Care Medicine.
Keywords

Full text: Available Collection: Databases of international organizations Database: English Web of Science Type of study: Prognostic study Language: English Journal: International Journal of Gerontology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: English Web of Science Type of study: Prognostic study Language: English Journal: International Journal of Gerontology Year: 2022 Document Type: Article